Amgen's best-selling medicine is safe from biosimilar competition for now.
News & Analysis: Amgen
The big biotech's CEO and CFO talk about what you can expect from Amgen over the next few years.
Which stock wins in a battle between these two big biotechs?
Amgen is acquiring Otezla, and The Medicines Company unveils stellar data for its cholesterol treatment.
Two presentations at the World Conference on Lung Cancer will make a big difference for at least four different drugmakers.
Patent cliffs and pipeline risks are among the reasons these biologic drug specialists are attractively priced today.
Bristol-Myers Squibb and Celgene made a deal to sell a blockbuster drug to Amgen, and Disney and Target are forming a retail collaboration.
Here's who wins the most from the sale of Otezla.
One of biotech's longest-running buyout rumors is picking up steam again.
Rumors that Amgen plans to buy Alexion might not become reality. But a deal would make a lot of sense.